Celularity Inc Ordinary Shares - Class A CELU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.38
- Day Range
- $1.36–1.64
- 52-Week Range
- $0.56–2.55
- Bid/Ask
- $1.55 / $1.61
- Shares Outstanding
- 32.45M
- Market Cap
- $51.92M
- Volume/Avg
- 221,844 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 115
- Website
- https://www.celularity.com
Valuation
|
Metric
|
CELU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.99 |
Price/Cash Flow | — |
Price/Earnings
CELU
Financial Strength
|
Metric
|
CELU
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.09 |
Interest Coverage | −14.28 |
Quick Ratio
CELU
Profitability
|
Metric
|
CELU
|
|---|---|
Return on Assets (Normalized) | −58.62% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −198.26% |
Return on Assets
CELU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|btkGT^w | LOCK|hDQ@& | $128B | |||
| Moderna Inc
MRNA
| LOCK|<SDk?G | LOCK|@M? | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%>>!!% | LOCK|#q%L# | $76B | |||
| argenx SE ADR
ARGX
| LOCK|<!LRn# | LOCK|dmC | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@>gPNcQ | LOCK|s! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&byGb$ | LOCK|!C^<< | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$@>&Q<vX | LOCK|yt$Z | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&k<^Vmp | LOCK|xH | $24B | |||
| Incyte Corp
INCY
| LOCK|^Sg^!bX | LOCK|?> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|K!PHb& | LOCK|<v | $15B |
United States